Table 1 The concentration of the percent effects, EC₂₀, EC₂₅, EC₅₀, EC₇₅, EC₉₀ and EC₉₈ of pembrolizumab, nivolumab, durvalumab or atezolizumab required for the recovery from the PD-1-mediated suppression of IL-2 production from T cells

EC₂₀ (95% CI)

0.07804

0.3389

0.02113

0.02095

0.02118–0.1680

0.1390–0.6495

0.01163–0.03035

0.008643–0.03598

EC₂₅ (95% CI)

0.1074

0.4734

0.02431

0.02511

0.03481–0.2143

0.2217–0.8497

0.01444–0.03383

0.01155–0.04090

EC₅₀ (95% CI)

0.3629

1.695

0.04146

0.05018

0.1981–0.6492

0.9932–3.329

0.03134–0.05420

0.03306–0.07170

EC₇₅ (95% CI)

1.227

6.07

0.07073

0.1003

0.6103–3.189

2.893–21.44

0.04732–0.1028

0.06622–0.1632

EC₉₀ (95% CI)

4.146

21.74

0.1207

0.2004

1.423–20.92

7.264–154.3

0.06179–0.2261

0.1061–0.4603

EC₉₈ (95% CI)

27.13

155.5

0.275

0.5828

4.828–434.9

28.01–3412

0.09277–0.8269

0.2097–2.582